BEUDAMED
    FDA Adverse Event Injury Summary report: N

    COOLSCULPTING SYSTEM

    MDR report key: 11794571 · Received May 7, 2021

    Report

    Report Number
    3007215625-2021-01275
    Event Type
    Injury
    Date Received
    May 7, 2021
    Date of Event
    January 1, 2021
    Report Date
    March 13, 2025
    Manufacturer
    ALLERGAN PLEASANTON
    Product Code
    OOK
    PMA / PMN Number
    K160259
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    CA
    Reporter Occupation
    OTHER
    Health Professional
    N

    Narratives

    Additional Manufacturer Narrative · 0

    ADDITIONAL, CHANGED, AND/OR CORRECTED DATA. SUPPLEMENTAL MEDWATCH IS BEING SUBMITTED TO CORRECT THE G3 FIELD WHICH WAS LEFT BLANK IN THE PREVIOUSLY SUBMITTED MEDWATCH.

    Additional Manufacturer Narrative · 0

    CORRECTED DATA: A4, A6, D1, AND D4. CORRECTION TO G.3. AWARE DATE OF INITIAL MEDWATCH 3007215625-2021-01275. AWARE DATE SHOULD HAVE BEEN LISTED AS 16/APRIL/2021. CORRECTION TO G.3. AWARE DATE OF SUPPLEMENTAL MEDWATCH 3007215625-2021-01275-1. AWARE DATE SHOULD HAVE BEEN LISTED AS 8/FEB/2023. THIS IS A KNOWN POTENTIAL ADVERSE EVENT ADDRESSED IN THE PRODUCT LABELING. ACCORDING TO THE COOLSCULPTING USER MANUAL, UNDER RARE ADVERSE EVENTS, PARADOXICAL ADIPOSE HYPERPLASIA (PH) IS CHARACTERIZED BY A VISIBLY ENLARGED TISSUE VOLUME WITHIN THE TREATMENT AREA, WHICH MAY DEVELOP TWO TO FIVE MONTHS AFTER TREATMENT. SURGICAL INTERVENTION MAY BE REQUIRED. PH IS NOT RELATED TO ANY COOLSCULPTING DEVICE FAILURE MODE BUT IT IS INCLUDED IN THE RISK MANAGEMENT FILES OF THE DEVICE BECAUSE IT IS A RISK THAT IS INHERENT TO THE USE CRYOLIPOLYSIS FOR LOCALIZED FAT REDUCTION. A SUPPLEMENTAL REPORT WILL BE SUBMITTED IF AND WHEN ADDITIONAL INFORMATION IS OBTAINED.

    Description of Event or Problem · 0

    A TREATMENT PROVIDER REPORTED A PATIENT WHO WAS TREATED ON (B)(6) 2020 TO THE BILATERAL SUBMENTAL USING THE COOLMINI APPLICATOR A PRESENTED WITH POSSIBLE PARADOXICAL HYPERPLASIA. THE PATIENT FIRST NOTICED THE SYMPTOMS ON (B)(6) 2020.

    Description of Event or Problem · 0

    ALLERGAN AESTHETICS RECEIVED A REPORT THAT A PATIENT RECEIVED A COOLSCULPTING TREATMENT TO THE SUBMENTAL ON (B)(6) 2020 USING THE COOLMINI APPLICATOR A PRESENTED WITH POSSIBLE PARADOXICAL HYPERPLASIA.

    Additional Manufacturer Narrative · 1

    THE FOLLOWING INFORMATION IS IN THE COOLSCULPTING USER MANUAL: PARADOXICAL HYPERPLASIA IS CHARACTERIZED BY A VISIBLY ENLARGED TISSUE VOLUME WITHIN THE TREATMENT AREA, WHICH MAY DEVELOP TWO TO FIVE MONTHS AFTER TREATMENT. SURGICAL INTERVENTION MAY BE REQUIRED.

    Description of Event or Problem · 1

    A TREATMENT PROVIDER REPORTED A PATIENT WHO WAS TREATED ON (B)(6) 2020 TO THE BILATERAL SUBMENTAL USING THE COOLMINI APPLICATOR A PRESENTED WITH POSSIBLE PARADOXICAL HYPERPLASIA. THE PATIENT FIRST NOTICED THE SYMPTOMS IN (B)(6) 2020.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    689797 COOLSCULPTING SYSTEM DERMAL COOLING PACK/VACUUM/MASSAGER OOK ALLERGAN PLEASANTON NI

    Patients

    Seq Age Sex Outcome Treatment
    1 36 YR Female